• QuartzBio, life science technology company providing portfolio-scale sample and biomarker intelligence software for clinical-stage biopharma, secured strategic growth investment and controlling interest from private equity firm Eir Partners.
• Deal funds product development and scaling of its vendor-agnostic, AI-enabled platform used to manage biospecimen collection and biomarker data across clinical trial portfolios.
• Bourne Partners Holdings LLC acted as exclusive financial adviser to QuartzBio; transaction terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bourne Partners Holdings LLC published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.